Origin of the Neonatal Gut Microbiota and Probiotic Intervention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aim to evaluate the composition and origin of the neonatal gut microbiota after birth and Probiotic intervention. Samples were obtained from a total of 30 pregnant individuals and their offspring, divided into control group and porbiotics group. Postpartum human milk and infant fecal specimens were collected for a period of 6 months. The samples were analyzed using 16S rRNA amplicon sequencing of the V3-V4 region to evaluate the microbial composition. The Shannon index, Simpson index and nonmetric multidimensional scaling were used to evaluate the diversity of the microbiota, while the co-occurrence network and LEfSe were used to evaluate the characteristics of the microbiota of pregnancies and their infants in each groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis

NCT02552706

Necrotizing Enterocolitis Death

UNKNOWN NA

Impact of Probiotics Supplement on the Gut Microbiota in Caesarean-born Infants

NCT05086458

Gut Microbiota

UNKNOWN NA

Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm

NCT02060084

Disorder of Stomach Function and Feeding Problems in Newborn Feeding and Eating Disorders of Childhood

COMPLETED PHASE4

Effect of Probiotics on the Digestibility and Immunity in Infants

NCT02317406

Gastrointestinal Tract Flora Composition

COMPLETED NA

Whether Probiotics Use in Neonate and Infant Improve Their Mother's Life Quality

NCT04741971

Postpartum Depression Quality of Life Functional Gastrointestinal Disorders +1 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design and participants A total of 30 samples were obtained from pregnant individuals receiving antenatal care at the 1st Affiliated Hospital of Jinan University. Informed consent was obtained from pregnant women (at least 32 gestational weeks) who met the inclusion criteria. Newborns were followed until 14 days after natural delivery. Pregnant inclusive criteria were: 1. Chinese woman who is pregnant with a single fetus; 2. First pregnancy and term delivery. Newborns' inclusive criteria were: 1. Normal weight (\>2500 g, \<4000 g); 2. Term Infant (\>37 weeks, \<42 weeks). 3. Natural birth. Pregnanct exclusive criteria were: 1. Gastrointestinal disease or family history; 2. Vaginitis before pregnancy; 3. Antibiotic usage during pregnancy; 4. Hypertension, Diabetes Mellitus, Hyperthyroidism, Hypothyroidism, Autoimmune Disease, or Other Endocrine and Metabolic Disease; 5. Gestational Hypertensive Disease, Gestational Diabetes Mellitus or Other Gestational Disease; 6. Transfusion History, Organ Transplantation History or Immunotherapy History. Newborn's exclusive criteria were: 1. Abnormal weight (\>4000 g, \<2500 g); 2. With Congenital Diseases;3. Intrapartum Fetal Complication.

Probiotic management In the investigators' study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery, and those in the control group took no pills.

Fecal, vaginal secretion, placental, and meconium collection Fecal collection Feces from pregnant patients were collected twice-between weeks 32 and 34 and before natural labor. Feces collected at weeks 32-34 were collected internally, thereby avoiding contamination with foreign material. The feces were stored in a domestic refrigerator and transferred to the laboratory freezer at -80 ºC for 24 hours. Feces collected before labor were obtained in the hospital and transferred to the laboratory freezer within 30 min of collection.

Vaginal secretion collection Vaginal secretions were collected twice between weeks 32 and 34 and before natural labor. The pregnant woman was asked to not engage in sexual behavior, clean the vulva, clean the vagina, or use vaginal medicine within 48 hours before sample collection. Vaginal secretions before natural labor were collected before membrane rupture occurred. The samples were transferred to the laboratory freezer within 30 min of collection, thereby avoiding contamination by foreign material.

Placenta collection Placenta samples ranging from the entire umbilical cord to 3 cm were collected by stripping the amniotic membrane after natural birth. The blood was rinsed with sterile saline. Four to six pieces of placenta were sampled from the fetal surface. Each piece had a volume of approximately 1 cm3. The placenta sample was transferred to the laboratory freezer within 30 min of collection.

Meconium collection Meconium was collected three times on the 1st day, the 3rd day, and the 14th day after natural delivery On the 1st day and 3rd day, meconium was collected internally, thereby avoiding contamination with foreign material in the hospital, and was transferred to the laboratory freezer within 30 min of collection. On the 14th day, meconium was collected, stored in a domestic refrigerator, and then transferred to a laboratory freezer within 24 hours of collection.

When infants were 6 months old, postpartum milk was collected by two full-time members of the research group. The human milk samples were collected according to a standardized protocol. Before collecting the samples, the nursing mothers were required to clean the nipple and areola with soap and water. A total sample volume of 6 ml was collected in a sterile tube. Additionally, infant fecal samples were collected at the 6th month postpartum. After collection, the samples were stored with dry ice for transportation to the laboratory immediately. Upon arrival at the laboratory, the samples were briefly thawed to allow for accurate aliquoting. Each sample was then divided equally into smaller frozen storage tubes. The divided samples were promptly refrozen and stored in a freezer at -80°C within 4 hours after collection. This process ensured that the samples were handled with minimal temperature fluctuations to preserve their integrity.

Fecal samples from the infants were collected internally in sterile and dedicated collecting boxes, thereby avoiding any contamination with foreign material. These samples were stored in a domestic freezer (-20°C) and transferred to a laboratory freezer at -80°C within 24 hours using a cryogenic transport container to ensure they remained frozen during the transfer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

pregnancies in control group need no intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

probiotics group

pregnancies in probiotics group need probiotics management

Group Type EXPERIMENTAL

Probiotic Blend Oral Tablet

Intervention Type DRUG

In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic Blend Oral Tablet

In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Pregnant inclusive criteria were:

1. Chinese woman who is pregnant with a single fetus;
2. First pregnancy and term delivery.

Newborns' inclusive criteria were:

1. Normal weight (\>2500 g, \<4000 g);
2. Term Infant (\>37 weeks, \<42 weeks).
3. Natural birth.

Pregnancy exclusive criteria were:

1. Gastrointestinal disease or family history;
2. Vaginitis before pregnancy;
3. Antibiotic usage during pregnancy;
4. Hypertension, Diabetes Mellitus, Hyperthyroidism, Hypothyroidism, Autoimmune Disease, or Other Endocrine and Metabolic Disease;
5. Gestational Hypertensive Disease, Gestational Diabetes Mellitus or Other Gestational Disease;
6. Transfusion History, Organ Transplantation History or Immunotherapy History.

Newborn's exclusive criteria were:

1. Abnormal weight (\>4000 g, \<2500 g);
2. With Congenital Diseases;3. Intrapartum Fetal Complication.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes